Zegalogue Injection, Solution
Product Images NDC 0169-1913

Product Visual Gallery

This gallery contains 27 technical images submitted to the FDA as part of the official labeling for Zegalogue (NDC 0169-1913). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (AI)

Zegalogue 0.6 mg/0.6 mL (dasiglucagon) injection autoinjector carton label. The label indicates it is for subcutaneous injection, prescription use only, and intended for emergency use for very low blood sugar. Manufactured by Novo Nordisk, the carton contains 1 single-dose autoinjector and prescribing information. Storage instructions include refrigeration between 2°C to 8°C (36°F to 46°F) or room temperature storage in a protective case for up to 12 months.*

FDA Label Image

Chemical Structure (Dasiglucagon 01)

Chemical structure diagram of dasiglucagon, illustrating its peptide chain with labeled amino acid residues. The depiction shows the specific sequence and molecular connectivity characteristic of this active ingredient used in injection solutions.*

FDA Label Image

Figure 1 (Dasiglucagon 02)

A line graph showing the mean glucose concentration (mg/dL) over time (minutes) after administration of Zegalogue. The graph plots mean glucose increasing steadily from about 50 mg/dL at 0 minutes to over 220 mg/dL by 90 minutes, representing glucose response kinetics.*

FDA Label Image

Figure 2 (Dasiglucagon 03)

Line graph depicting mean glucose levels (mg/dL) over time (minutes) for two age groups, 6-11 years and 12-17 years. The glucose levels increase over a 60-minute period, with data points connected by lines specific to each age group, showing similar trends in both groups.*

FDA Label Image

Figure 3 (Dasiglucagon 04)

A line chart comparing time to plasma glucose recovery over 45 minutes for Zegalogue and placebo. The x-axis represents time in minutes, and the y-axis shows the proportion of glucose recovery. The Zegalogue line rises quickly to 1.0, while the placebo line rises more gradually, reaching about 0.7 by 45 minutes.*

FDA Label Image

Figure 4 (Dasiglucagon 05)

A Kaplan-Meier survival curve chart comparing time to plasma glucose recovery in minutes between Zegalogue (solid line) and placebo (dashed line). The x-axis represents time in minutes up to 45, and the y-axis shows the proportion of subjects achieving glucose recovery, ranging from 0 to 1. The chart shows faster glucose recovery for Zegalogue compared to placebo.*

FDA Label Image

Figure (Dasiglucagon 06)

An instructional diagram detailing how to determine the new 12-month expiration date for Zegalogue (dasiglucagon) injection solution when removed from refrigeration for room temperature storage. It highlights writing the new expiration date on the label of the red protective case, includes an example with dates, and illustrates a calendar to explain the 12-month expiration period.*

FDA Label Image

Pfs-description.jpg (Dasiglucagon 07)

Illustration of Zegalogue (dasiglucagon) 0.6 mg/0.5 mL prefilled syringe for subcutaneous injection. The image shows components including the red protective case, gray cap, plunger rod, and gray needle cover. It highlights the syringe as single-dose, ready to use for emergency treatment of very low blood sugar.*

FDA Label Image

Figure (Dasiglucagon 08)

An instructional illustration showing recommended injection sites for subcutaneous administration. The front view highlights areas on the abdomen and front thighs, while the back view highlights areas on the upper and lower back of the thighs.*

FDA Label Image

Figure (Dasiglucagon 09)

An instructional illustration showing a hand pulling a cap straight off a small vial or container, with an arrow indicating an upward removal motion. The image likely depicts the first step in preparing an injection device or medication vial for use.*

FDA Label Image

Figure (Dasiglucagon 10)

An instructional illustration showing a person removing a protective cap from a syringe or injection pen, likely demonstrating preparation steps for a subcutaneous injection of the medication Zegalogue (dasiglucagon).*

FDA Label Image

Figure (Dasiglucagon 11)

An instructional illustration showing a hand holding a syringe at a 45-degree angle to the skin, demonstrating the proper technique for subcutaneous injection.*

FDA Label Image

Figure (Dasiglucagon 12)

An instructional illustration showing a hand holding a syringe and injecting a solution subcutaneously into the skin. The image depicts the method for subcutaneous injection, relevant to the administration of the Zegalogue (dasiglucagon) injection, solution 0.6 mg/0.6 mL by Novo Nordisk.*

FDA Label Image

Figure (Dasiglucagon 13)

An instructional illustration showing a hand holding a syringe for subcutaneous injection, with an arrow pointing to a skin surface, indicating the injection site and technique.*

FDA Label Image

Figure (Dasiglucagon 14)

An instructional illustration showing the proper way to insert a syringe needle into a vial or container. The image depicts a hand holding a syringe, angled downward as it penetrates a rubber stopper on top of a vial in a red and white box.*

FDA Label Image

Figure (Dasiglucagon 15)

This instructional text panel explains how to record a new 12-month expiration date on the Zegalogue injection label if the product is removed from refrigeration and stored at room temperature. It includes example label images illustrating where to write the updated expiration date and highlights that Zegalogue will expire on the earlier of the two dates shown.*

FDA Label Image

Ai-description.jpg (Dasiglucagon 17)

Illustration of the Zegalogue autoinjector (dasiglucagon) 0.6 mg/0.6 mL showing its red protective case and gray lid, with labels identifying parts such as the needle end, yellow needle guard, gray cap, and medicine window before and after injection. The diagram visually explains the autoinjector components and the appearance change in the medicine window post-injection.*

FDA Label Image

Figure (Dasiglucagon 18)

Illustration showing recommended injection sites for subcutaneous administration of Zegalogue (dasiglucagon) injection. Front view highlights the abdomen and thigh areas, while the back view highlights the upper arm and buttocks as suitable injection sites.*

FDA Label Image

Figure (Dasiglucagon 19)

Illustration showing the removal of a gray protective cap from the top of a Zegalogue (dasiglucagon) injection pen. The image highlights proper preparation before subcutaneous injection.*

FDA Label Image

Figure (Dasiglucagon 20)

An instructional diagram showing a hand holding a gray cap being removed from the orange needle tip of a prefilled syringe, indicating preparation for subcutaneous injection.*

FDA Label Image

Figure (Dasiglucagon 21)

An instructional illustration showing a hand holding a prefilled injection device administering a subcutaneous dose. A downward arrow indicates pressing the device against the skin, with a "Click" sound effect denoting activation.*

FDA Label Image

Figure (Dasiglucagon 22)

An instructional illustration showing how to use a subcutaneous injection device. It depicts a hand holding the device with instructions to hold it for 10 seconds until a click is heard, indicating that the full dose has been administered, confirmed by a red indicator.*

FDA Label Image

Figure (Dasiglucagon 23)

An instructional illustration showing a hand holding a Zegalogue injection pen in an upright position with the needle pointing downward toward the skin, indicating the preparation or administration of the subcutaneous injection.*

FDA Label Image

Figure (Dasiglucagon 24)

An instructional illustration showing a vial with a red cap and a dropper being used to draw liquid from the vial. The background is light blue with a shadow beneath the vial, depicting the step for withdrawing medication from the container for injection.*

FDA Label Image

Carton (PFS)

Zegalogue (dasiglucagon) injection 0.6 mg/0.6 mL prefilled syringe packaging label. The label highlights emergency use for very low blood sugar and indicates it is a single-dose injection for subcutaneous use. It includes storage instructions, manufacturer Novo Nordisk, and patient safety warnings.*

FDA Label Image

Carton (PFS)

Packaging label for Zegalogue (dasiglucagon) injection 0.6 mg/0.6 mL prefilled syringe. The label indicates a 2-pack of single-dose prefilled syringes for subcutaneous injection, labeled for emergency use for very low blood sugar. The carton includes storage instructions, prescribing information, and Novo Nordisk as the labeler.*

FDA Label Image

Carton-ai-2ct (Image 01)

Zegalogue (dasiglucagon) injection 0.6 mg/0.6 mL autoinjector carton label for subcutaneous use, containing 2 single-dose autoinjectors. The packaging highlights emergency use for very low blood sugar and includes storage instructions, prescribing information, and Novo Nordisk as the labeler.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.